Omilancor is under clinical development by NImmune Biopharma and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Omilancor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Omilancor overview
Omilancor (BT-11) is under development for the treatment of inflammatory bowel disease (IBD) like crohn's disease and ulcerative colitis, eosinophilic esophagitis, psoriasis, atopic dermatitis. The drug candidate is administered through oral route. The drug candidate is an arebis (benzimidazoyl) terephthalanilide derivative and targets lanthionine synthetase component C-like protein 2 (LANCL2). It was also under development for the treatment of type 2 diabetes.
See Also:
NImmune Biopharma overview
NImmune Biopharma a late-stage precision immunology biopharmaceutical company which develop biomarker-driven immunoregulatory therapeutics. The company is headquartered in Blacksburg, Virginia, the US.
For a complete picture of Omilancor’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
